We await with interest the outcome of the Government's consultation on the Guidance on NHS patients who wish to pay for additional private care.

In addition we are awaiting the publication of a set of core principles to inform how PCTs make decisions on the funding of new drugs and the publication of detailed good practice guidance for PCTs about the processes they should have in place to make decisions about the funding of new drugs and the handling of exceptional cases.

We will see more and more demands for high cost drugs so there is still likely to be a spotlight on this challenging area of healthcare law.